Released Presentations

  • F1 : HEALTH STATE UTILITY (HSU) GOOD PRACTICES TASK FORCE RECOMMENDATIONS FOR IDENTIFICATION AND USE OF HSU DATA IN COST-EFFECTIVENESS IN DECISION MODELLING

    Presentation

    A. Simon Pickard
    PhD, Professor, University of Illinois at Chicago, College of Pharmacy, Chicago, USA
    Bruce Crawford
    MA, MPH, Senior Principal, IMS Japan K.K., Real-World Evidence Solutions, Japan & APAC, Minato-ku, Tokyo, Japan
    John E. Brazier
    PhD, Professor, University of Sheffield, Health Economics, School of Health and Related Research, Sheffield, UK
  • F2 : HANDLING MISSING VALUES IN REAL-WORLD DATA: ARE THERE CHALLENGES FOR REGULATORY DECISIONS FOR MEDICAL PRODUCTS?

    Presentation

    Judith J. Stephenson
    SB, SM, Principal Scientist, Survey Research, HealthCore, Inc., Wilmington, USA
    Nneka C. Onwudiwe
    PhD, PharmD, MBA, PRO/PE Regulatory Reviewer, U.S. Food and Drug Administration, Office of Prescription Drug Promotion, CDER, Silver Spring, USA
    Samuel Wilson
    PhD, BS, MS, Associate Director-Statistics, Astellas Pharmaceuticals US, Inc., Northbrook, USA
    Helene Karcher
    X-Eng, MIT PhD, Managing Vice-President, Global Head, Real World Modeling, LASER Analytica, London, UK
    Laurence Djatche
    PharmD, Health Economics and Outcomes Research Post-Doctoral Fellow, Thomas Jefferson University, College of Population Health, Philadelphia, USA
  • F3 : DEFINING PATIENT CENTEREDNESS AND ENGAGEMENT IN HEOR: PROPOSED DEFINITION AND STAKEHOLDER RESPONSE

    Presentation

    Rachel L. Harrington
    BA, Pre-Doctoral Fellow, University of Illinois at Chicago, Institute for Health Research and Policy/College of Pharmacy, Chicago, USA
    Suzanne Schrandt
    JD, Director, Patient Engagement, Arthritis Foundation, Atlanta, USA
    Eleanor M. Perfetto
    PhD, MS, Professor, Pharmaceutical Health Services Research, University of Maryland, National Health Council, and Senior Vice President, Strategic Initiatives, Washington, USA
    Sarah Donelson
    MA, Lead, Patient-Centered Research, Genentech, San Francisco, USA
  • F4 : THE ISPOR HEOR COMPETENCIES FRAMEWORK™: GUIDING PROFESSIONAL DEVELOPMENT FOR THE FIELD OF HEOR

    Presentation

    Laura T. Pizzi
    PharmD, MPH, Professor and Director, Rutgers University, Center for Health Outcomes Policy and Economics, Piscataway, USA
    Bill Marder
    PhD, MA, BA, Chief Data Strategist, IBM Watson Health, Cambridge, USA
  • F5 : ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK

    Presentation

    Sang-Soo Lee
    MBA, Director, Corporate Affairs, Medtronic Korea, Co., Ltd., Seoul, South Korea
  • F5 : ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK
  • F5 : ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK
  • F6 : VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS EMERGING GOOD PRACTICES TASK FORCE: FINAL RECOMMENDATIONS

    Presentation

    Rachael Fleurence
    PhD, Program Director of Comparative Effectiveness Research Methods and Infrastructure Program, Patient Centered Outcomes Research Institute (PCORI), Washington, USA
    Anirban Basu
    PhD, Professor & Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, USA
    James F. Murray
    PhD, Research Fellow, Eli Lilly and Company, Global Health Outcomes - COE, Carmel, USA
    Lotte Steuten
    PhD, Member, Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, USA
    Gillian D Sanders Schmidler
    PhD, Deputy Director, Academics and Professor of Population Health Sciences, School of Medicine, Duke University, The Robert J. Margolis, MD, Center for Health Policy, Washington, USA
  • F7 : ENABLING ISPOR MEMBER AND PATIENT ADVOCACY GROUP RESEARCH COLLABORATION: A VOLUNTEER PLAN

    Presentation

    Richard J. Willke
    PhD, Vice President, Outcomes & Evidence Lead CV/Metabolic, Pfizer Inc., Pain, Urology, Gender Health, Global Health & Value, New York, USA
    Laura T. Pizzi
    PharmD, MPH, Professor and Director, Rutgers University, Center for Health Outcomes Policy and Economics, Piscataway, USA
    Brian Ung
    PharmD, MS, Post-Doctoral Fellow, Celgene Corporation, US Health Economics and Outcomes Research, Summit, USA
    Jason Harris
    BA, Associate Director of Policy and Programs, National Health Council, Washington, USA
  • F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

    Presentation

    Makoto Kobayashi
    PhD, M.Eng., Director and COO, CRECON Medical Assessment Inc., Tokyo, Japan
  • F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

    Presentation

    Sukyeong Kim
    PHD, Director, National Evidence-Based Healthcare Collaborating Agency, Coordinating Center for National Health Clinical Research, Seoul, Korea, Republic of (South)
  • F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

    Presentation

    Jitendar Sharma
    PhD, Head-Division of Healthcare Technology, Ministry of Health & Family Welfare, National Health Systems Resource Center, New Delhi, India
  • F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

    Presentation

    Jianwei Xuan
    MD, PhD, Advisory Professor, Fudan University, School of Public Health, Shanghai, China
  • F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?

    Presentation

    Bor-Sheng Ko
    MD, PhD, Attending Physician and Clinical Assistant Professor, National Taiwan University Hospital, BMT Unit and Hematology Division, Department of Internal Medicine, Taipei, Taiwan
  • F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS

    Presentation

    Ramiro E. Gilardino
    MD, MSc, Director, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), Global Networks Latin America, Lawrenceville, USA
  • F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS

    Presentation

    Juan Carlos Alandete Manotas
    MD, MSc, MPH, MACS LATAM, Bayer, Whippany, USA
  • F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS

    Presentation

    Louis Garrison
    PhD, 2015-2016 ISPOR President-elect, Board of Directors and Professor, University of Washington, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, Seattle, USA
  • F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS

    Presentation

    Boxiong Tang
    MD, PhD, Partner, Perspective, Collegeville, USA
  • W1 : TIME TO LOOK BEYOND KAPLAN-MEIER CURVES? CHALLENGES AND OPPORTUNITIES IN OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TRIALS -- SCIENTIFIC RATIONALE FOR USING PATIENT-LEVEL BIOMEDICAL INFORMATION (Advanced Workshop)

    Presentation

    Yiduo Zhang
    PhD, Director, Health Economics and Payer Analytics, AstraZeneca, Global Payer Evidence and Pricing, Gaithersburg, USA
  • W1 : TIME TO LOOK BEYOND KAPLAN-MEIER CURVES? CHALLENGES AND OPPORTUNITIES IN OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TRIALS -- SCIENTIFIC RATIONALE FOR USING PATIENT-LEVEL BIOMEDICAL INFORMATION (Advanced Workshop)

    Presentation

    Pralay Mukhopadhyay
    PhD, Statistician, Astrazeneca, Gaithersburg, USA